Metavention Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 23
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $65M
Latest Deal Amount
  • Investors
  • 5

Metavention General Information

Description

Developer of transcatheter devices designed to modulate sympathetic nervous system activity. The company's devices treat over-active sympathetic nerves associated with elevated glucose and abnormal liver function while utilizing standard interventional vascular techniques to treat patients with Type 2 diabetes, enabling physicians and medical practitioners to acquire a new tool that can be effectively used in the diagnosis and subsequent treatment of patients suffering from type 2 diabetes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Primary Office
  • 10900 73rd Avenue North
  • Suite 101
  • Maple Grove, MN 55369
  • United States
+1 (612) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Metavention Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 15-Dec-2017 $65M 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B3) 01-Dec-2015 000 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series B) 07-Feb-2014 $12M $14.7M 000.00 Completed Clinical Trials - General
1. Early Stage VC (Series A) 16-Oct-2013 $2.73M $2.73M 000.00 Completed Clinical Trials - General
To view Metavention’s complete valuation and funding history, request access »

Metavention Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series BNV 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series BV 2,780,656 $0.000100 $0.34 $4.26 $4.26 1x $2.74 1.9%
Series A 2,729,300 $0.000100 $0.08 $1 $1 1x $0.92 1.3%
To view Metavention’s complete cap table history, request access »

Metavention Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of transcatheter devices designed to modulate sympathetic nervous system activity. The company's devices treat
Therapeutic Devices
Maple Grove, MN
23 As of 2021
000.00
00.00 0000-00-00
0000000000 0 000.00

0000000

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
00000000000 0000000
Lexington, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
00000000000 0000000
Ashkelon, Israel
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Metavention Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fractyl Health Venture Capital-Backed Lexington, MA 00 00000 00000000000 00000
0000000 0000000 Venture Capital-Backed Ashkelon, Israel 00 0000 00000000000 0000
00000000 Venture Capital-Backed Birkerød, Denmark 00 0000 0000000 0000 0000
000000 00000000000 Private Equity-Backed Durham, NC 00 000.00 0000000 0000 000.00
00 000 00000000000 Venture Capital-Backed New York, NY 00 00.000 0000000000 0 00.000
You’re viewing 5 of 22 competitors. Get the full list »

Metavention Executive Team (6)

Name Title Board Seat Contact Info
Todd Berg Chief Executive Officer & President
James Ness Consulting Chief Financial Officer
Scott Vafai MD Co-Founder
Tony Vrba Vice President, Research & Development
You’re viewing 4 of 6 executive team members. Get the full list »

Metavention Board Members (7)

Name Representing Role Since
Ilan Lovinsky JD Self Board Member 000 0000
Kevin Hykes Self Member of Board of Directors 000 0000
Kirk Nielsen Versant Ventures Board Member 000 0000
Peter McNerney Self Board Member 000 0000
Timothy Mills Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Metavention Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metavention Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horowitz Management Family Office Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Richard King Mellon Foundation Limited Partner Minority 000 0000 000000 0
Sanderling Ventures Venture Capital Minority 000 0000 000000 0
Versant Ventures Venture Capital Minority 000 0000 000000 0
To view Metavention’s complete investors history, request access »